Pretransplant MRD: the light is yellow, not red
- PMID: 22791775
- DOI: 10.1182/blood-2012-05-427443
Pretransplant MRD: the light is yellow, not red
Abstract
In the study reported in this issue of Blood by Leung et al, detectable minimal residual disease (MRD) before hematopoietic stem cell transplantation (HSCT) was found to be prognostic for outcome, but did not prevent cure for children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Comment on
-
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.Blood. 2012 Jul 12;120(2):468-72. doi: 10.1182/blood-2012-02-409813. Epub 2012 Apr 19. Blood. 2012. PMID: 22517895 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources

